Familial IBD Early Risk
Official title: Familial Inflammatory Bowel Disease Early Risk (Fiber) Study
Run by Seattle Children's Hospital · NCT07791862 · Data updated 2026-11-12
This study tests whether clinical, environmental, and immune factors in first-degree relatives of people with Crohn’s disease or ulcerative colitis can predict who will develop IBD.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years to 55 Years |
| Sex | All |
| Enrollment | 7000 (estimated) |
| Sponsor | Seattle Children's Hospital Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Status | Recruiting |
| Started | March 26, 2026 |
| Main results expected | February 2036 |
| Study ends | February 2036 |
| Registry record updated | August 28, 2026 |
| Trial ID | NCT07791862 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are asymptomatic first-degree relatives (siblings or offspring) of a person with Crohn’s disease or ulcerative colitis, aged 0–55 years.
✕Probably not a fit
Individuals without a family history of IBD or those outside the specified age range may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The FIBER study is an observational investigation aimed at identifying triggers associated with the later development of inflammatory bowel disease by analyzing baseline characteristics and biosamples from asymptomatic first-degree relatives of IBD patients. Researchers will examine clinical, demographic, and immunologic factors, as well as dietary and environmental influences, to see which elements are linked to future IBD onset. Biosamples such as blood, urine, stool, saliva, and tissue will be collected for analysis using advanced immunologic and molecular techniques. The study focuses on multiplex families where multiple relatives are affected, to understand the combined influence of genetics, immunity, and environment beyond single-risk profiles.
Why it matters
Potential benefit: If successful, the study could improve risk prediction for IBD in high-risk relatives and inform early monitoring or prevention strategies.
How similar studies have gone: Previous observational work has linked family history and immune markers to IBD risk, but this study aims to integrate multi-omics and detailed exposure data in multiplex families.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Asymptomatic first degree relative (FDR) (siblings or offspring) of patients with CD or UC aged between 0 and 55 years. Exclusion Criteria: * Nonviable neonates and uncertain viability neonates * Antibiotic treatment within 3 months prior to recruitment * Individuals with the presence of a known diagnosis of IBD, or symptoms suggestive of IBD * Not within the age range of 0-55 years
Where it's running
-
Seattle Children's Hospital
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: David L Suskind, MD — Seattle Children's Hospital
- Study coordinator: Cylia Abrous, BS
- Email: cylia.abrous@seattlechildrens.org
- Phone: 206-987-4701
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarker Discovery and Validation Platform for Inflammatory Bowel Disease
Researchers are testing biomarker models to see if they can measure and predict inflammation and treatment response in people with Crohn's disease, ulcerative colitis, or related IBD.
-
Wearable data to spot IBD flareups in people with ulcerative colitis or Crohn's disease
This study tests whether heart‑rate variability from participants’ own wearables can help predict IBD flares.
-
Individualizing Anti-TNF Therapy in IBD
This study tests whether genetic markers can predict which anti-TNF–naïve IBD patients will respond to their first anti-TNF treatment.
-
LRG levels and IBD activity in European patients
This study will test whether Leucine-rich α2-glycoprotein (LRG) levels reflect disease activity in adults with Crohn’s or ulcerative colitis who are undergoing routine endoscopy in Europe.
-
Modafinil for Debilitating Fatigue in Quiescent IBD
A study will test whether modafinil can help adults with Crohn’s disease or ulcerative colitis who feel very fatigued even when their IBD is quiet.
-
CEDUR — German inflammatory bowel disease registry
This registry collects real-world health and treatment information from adults with Crohn's disease, ulcerative colitis, or indeterminate colitis in Germany to see how care, effectiveness, safety, and costs play out in routine practice.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.